Nandini Raghavan

Summary

Affiliation: Johnson and Johnson Pharmaceutical Research and Development
Country: USA

Publications

  1. pmc The ADAS-Cog revisited: novel composite scales based on ADAS-Cog to improve efficiency in MCI and early AD trials
    Nandini Raghavan
    Janssen Pharmaceutical Companies of Johnson and Johnson, Raritan, NJ, USA
    Alzheimers Dement 9:S21-31. 2013
  2. pmc Rare variant collapsing in conjunction with mean log p-value and gradient boosting approaches applied to Genetic Analysis Workshop 17 data
    Yauheniya Cherkas
    Epidemiology, Johnson and Johnson, 1125 Trenton Harbourton Road, Titusville, NJ 08560, USA
    BMC Proc 5:S94. 2011
  3. pmc Sparse learning and stability selection for predicting MCI to AD conversion using baseline ADNI data
    Jieping Ye
    Center for Evolutionary Medicine and Informatics, The Biodesign Institute, Arizona, State University, Tempe, AZ, USA
    BMC Neurol 12:46. 2012
  4. pmc Disease progression model in subjects with mild cognitive impairment from the Alzheimer's disease neuroimaging initiative: CSF biomarkers predict population subtypes
    Mahesh N Samtani
    Johnson and Johnson Pharmaceutical Research and Development, Clinical Pharmacology Department, Raritan, New Jersey 08869, USA
    Br J Clin Pharmacol 75:146-61. 2013
  5. doi request reprint A novel subject synchronization clinical trial design for Alzheimer's disease
    Timothy Schultz
    Janssen Pharmaceutical Companies of Johnson and Johnson, Raritan, NJ 08869, USA
    J Alzheimers Dis 31:507-16. 2012
  6. doi request reprint An improved model for disease progression in patients from the Alzheimer's disease neuroimaging initiative
    Mahesh N Samtani
    Johnson and Johnson Pharmaceutical Research and Development, Raritan, NJ, USA
    J Clin Pharmacol 52:629-44. 2012

Collaborators

  • Mahesh N Samtani
  • Eric Yang
  • Victor Lobanov
  • Allitia Dibernardo
  • Gerald Novak
  • Michael Farnum
  • Rudi Verbeeck
  • Timothy Schultz
  • Jieping Ye
  • Yauheniya Cherkas
  • Yingqi Shi
  • Vaibhav A Narayan
  • Vaibhav Narayan
  • Frank Defalco
  • Stephan Francke
  • Marsha A Wilcox

Detail Information

Publications6

  1. pmc The ADAS-Cog revisited: novel composite scales based on ADAS-Cog to improve efficiency in MCI and early AD trials
    Nandini Raghavan
    Janssen Pharmaceutical Companies of Johnson and Johnson, Raritan, NJ, USA
    Alzheimers Dement 9:S21-31. 2013
    ..A wealth of data exists in ADAS-Cog from both historical trials and contemporary longitudinal natural history studies that can provide insights about parts of the scale that may be better suited for MCI and early AD trials...
  2. pmc Rare variant collapsing in conjunction with mean log p-value and gradient boosting approaches applied to Genetic Analysis Workshop 17 data
    Yauheniya Cherkas
    Epidemiology, Johnson and Johnson, 1125 Trenton Harbourton Road, Titusville, NJ 08560, USA
    BMC Proc 5:S94. 2011
    ..When compared the result of this tree-based method with the list of single-nucleotide polymorphisms used in dataset simulation, in addition to correct SNPs we observe number of false positives...
  3. pmc Sparse learning and stability selection for predicting MCI to AD conversion using baseline ADNI data
    Jieping Ye
    Center for Evolutionary Medicine and Informatics, The Biodesign Institute, Arizona, State University, Tempe, AZ, USA
    BMC Neurol 12:46. 2012
    ..Different biosignatures for AD (neuroimaging, demographic, genetic and cognitive measures) may contain complementary information for diagnosis and prognosis of AD...
  4. pmc Disease progression model in subjects with mild cognitive impairment from the Alzheimer's disease neuroimaging initiative: CSF biomarkers predict population subtypes
    Mahesh N Samtani
    Johnson and Johnson Pharmaceutical Research and Development, Clinical Pharmacology Department, Raritan, New Jersey 08869, USA
    Br J Clin Pharmacol 75:146-61. 2013
    ....
  5. doi request reprint A novel subject synchronization clinical trial design for Alzheimer's disease
    Timothy Schultz
    Janssen Pharmaceutical Companies of Johnson and Johnson, Raritan, NJ 08869, USA
    J Alzheimers Dis 31:507-16. 2012
    ....
  6. doi request reprint An improved model for disease progression in patients from the Alzheimer's disease neuroimaging initiative
    Mahesh N Samtani
    Johnson and Johnson Pharmaceutical Research and Development, Raritan, NJ, USA
    J Clin Pharmacol 52:629-44. 2012
    ....